Creepy...*

Posted 10/10/2016. 

Folded...

"Jemele Hill has been suspended for two weeks for a second violation of our social media guidelines," ESPN said in a statement.

"She previously acknowledged letting her colleagues and company down with an impulsive tweet. In the aftermath, all employees were reminded of how individual tweets may reflect negatively on ESPN and that such actions would have consequences. Hence this decision."

ESPN told CNBC Hill was suspended not because of a single tweet but because of series of tweets that "brought the company into a conversation it didn't belong in."

In several tweets, Hill said a "more powerful statement" against Dallas Cowboys owner Jerry Jones was to boycott watching the team and buying its merchandise, as well as boycotting its advertisers. The tweet was in response to Jones' statements that any player who "disrespects the flag" by kneeling during the national anthem would not be allowed to play. Hill added on Twitter she was not advocating an NFL boycott, but pointing out an "unfair burden" for players on teams with anthem protest rules.

Some are terminated for much less.  

Half...

Nudged...

Richard Thaler 

Richard Thaler won the Nobel Prize in economics for his contributions to behavioral economics, the study of how humans may not always act as rationally as economists' models assume.

On Monday, the Royal Swedish Academy of Sciences awarded Thaler the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel 2017 at a ceremony from Stockholm. Thaler phoned into the ceremony to answer questions about his work.

In a response to a question on how he will spend the 9 million Swedish kronor ($1.1 million) in prize money, Thaler said:

"I will try to spend it as irrationally as possible."

Thaler, a professor at The University of Chicago Booth School of Business, is most well-known for his 2008 book "Nudge" co-authored with Cass Sunstein, a professor at The University of Chicago Law School.

The work discusses how humans are often irrational beings whose behavior can be influenced, or "nudged," through their environment.

Thaler has said his favorite example of a nudge is how adding flies to urinals in airports reduces spillage.  [CNBC-Evelyn Cheng]

Visa...

Turkey's justice minister said he hoped the United States would "review" its decision to suspend most visa services for Turkish citizens following the arrest of a U.S. consulate employee in Istanbul.

Meanwhile, Turkish authorities announced that a second employee of the U.S. consulate in Istanbul had been "invited" to the Istanbul's chief prosecutor's office to testify.

The U.S. suspended the issuing of visas for Turkish citizens hoping to visit or study in the United States after Turkey arrested U.S. consulate employee on allegations of espionage.  Turkey halted visa services in the U.S. in a tit-for-tat response.

Despite the seemingly friendly relations between U.S. President Donald Trump and Turkey's Recep Tayyip Erdogan, ties between the two countries are tense over the arrest of Topuz, a Turkish citizen, and several Americans over alleged ties to a movement led by U.S.-based cleric Fethullah Gulen, whom Turkey blames for last summer's coup attempt.

Did we or didn't we? That's the question.

Less Filling...

Less is More.  Just a thought.

Pharma...

Cancer drugs cost far less to develop than industry-backed research asserts, an analysis published asserts. Research and development costs are a major reason that drug companies justify high prices, so this dispute has a direct bearing on the cost of medical care.

The analysis, published in the current issue of JAMA Internal Medicine, concludes that it costs, on average, $650 million to develop a new cancer drug. The authors add in another $100 million or so to account for income those companies could have had if that money had been invested in the stock market instead of in new products.

That total is far lower than the $2.7 billion figure that the drug industry frequently points to when it justifies the soaring cost of medicine.

Prices of medications is higher since the market is not open and free. This is why in Canada and other similar countries prices are one third of the American market.

So the revenue from Marketing in US is more rewarding than R&D which is not the case in Europe.  Just a thought.

Reflection...

Glass...

Nothing much to talk about now a days. So here comes the next Hurricane. Days of continue pounding on what possibly will happen in the coming three days.

Nothing else can save us except a new election.

Marketing..

Shares of $17 billion drug stock Mylan NV (MYL) are in rally-mode , breaking out to nearly 19% gains on the heels of an FDA approval.

Mylan scored the FDA's blessing on its generic copy of Teva Pharmaceutical's (TEVA ) blockbuster multiple-sclerosis drug Copaxone, sparking a selloff in Teva as investors worry that generic competition will severely damage the $3.6 billion revenue stream Teva has banked on Copaxone in the last 12 months.

More importantly for Mylan shareholders, the FDA approval rights what's been a very shaky ship in 2017. Before today, Mylan had been staring down a 15% reduction in market value year to date, trailing the rest of the healthcare sector by a massive 35%. Wednesday's double-digit rally in Mylan helps to bridge that gap.

And there are signs of more upside ahead for Mylan from here.  Now the marketing begins.